Efficacy and safety of teclistamab in triple‐class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort

Documenti analoghi

• Correction to “Efficacy and safety of teclistamab in triple‐class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort”
  Pubblicazione: (2026)
• “Fast but not so furious”: A condensed step‐up dosing schedule of teclistamab for relapsed/refractory multiple myeloma
  di: Kevin C. Graf, et al.
  Pubblicazione: (2024)
• Carfilzomib use in patients with relapsed/refractory multiple myeloma in France: A national retrospective cohort study
  di: Cyrille Hulin, et al.
  Pubblicazione: (2024)
• Teclistamab for relapsed refractory multiple myeloma patients on dialysis
  di: P. Lebreton, et al.
  Pubblicazione: (2024)
• Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study
  di: Michael H. Tomasson, et al.
  Pubblicazione: (2024)